Multiplexed Capture Panels for Diagnostics and NGS

Team Dynamic Matrices | 2026-08-21

A single-target pulldown is a solved problem. Design one probe, optimize one set of hybridization conditions, capture one thing. Most sample prep chemistries, from magnetic bead-based pulldowns to classic hybridization baits, handle this case well enough. The trouble starts when you need ten targets, or fifty, in the same tube.

Multiplexed capture, pulling several distinct nucleic acid or protein targets out of a complex sample in a single reaction, is now central to two fast-growing application areas: diagnostic panels (infectious disease screens, cancer biomarker panels, pharmacogenomic panels) and NGS target enrichment (custom gene panels, exome-adjacent panels, low-abundance transcript capture). Both need the same thing from sample prep: consistent, specific recovery of every target in the panel, not just the easiest one.

This is where a lot of otherwise solid single-target methods start to show their seams.

Why Multiplexing Breaks Single-Target Assumptions

When you add more probes to one reaction, you are not just running the same reaction N times in parallel. You are introducing a new set of interactions:

Cross-reactivity between probes. Probes designed independently for different targets can partially hybridize to each other, especially if they share GC-rich stretches or common adapter sequences. In a single-target reaction this never surfaces. In a 20-plex panel it can quietly eat into your yield for several targets at once.

Uneven capture efficiency. Every probe has its own melting temperature, secondary structure profile, and binding kinetics. Run them all under one set of conditions optimized for the "average" probe, and the targets at the tails of that distribution underperform. In diagnostics, that unevenness can be the difference between detecting a low-abundance pathogen and missing it.

Nonspecific background that scales with panel size. Magnetic bead chemistries rely heavily on nonspecific charge-based or size-based adsorption alongside sequence-specific binding. Add more probes and more surface area, and the nonspecific carryover compounds. What was an acceptable background at one target becomes a real signal-to-noise problem at fifteen.

Cost that scales linearly, or worse, with panel breadth. Traditional hybridization capture (biotinylated RNA baits, for instance) requires a new synthesis run for every panel redesign. Adding or removing a single target from a 50-plex panel often means resynthesizing the whole bait set.

None of these problems are exotic. They are the reason panel design is treated as its own discipline rather than "single-target capture, repeated."

Design Principles That Actually Hold Up at Scale

A few practical rules tend to separate panels that perform uniformly from panels that quietly fail on their weakest targets.

Design probes as a set, not individually. Thermodynamic matching across the panel, ideally within a few degrees of melting temperature for every probe, keeps a single hybridization and wash condition from favoring some targets over others. This usually means iterating probe length and sequence position rather than taking the first candidate that binds the target region.

Screen for cross-hybridization computationally before synthesis. Pairwise sequence comparison across every probe in the panel catches the obvious collisions. It will not catch everything (secondary structure effects are harder to predict), but it removes the low-hanging conflicts cheaply.

Separate the specificity mechanism from the capture mechanism where possible. In bead-based systems, the same physical event (binding to the bead surface) handles both specificity and pulldown, so any nonspecific binding to that surface shows up directly as background. Systems where a sequence-specific "catcher" event is decoupled from the physical capture step tend to hold background lower as multiplexing increases, because nonspecific material never gets a route onto the capture surface in the first place.

Build in redesignability from day one. Panels change. A pathogen panel gains a new variant target, a biomarker panel drops an underperforming marker, an NGS panel needs to add a gene of interest mid-study. Chemistries where changing a target means swapping a short capture sequence, rather than resynthesizing an entire bait library, cut both the cost and the turnaround time of panel iteration substantially.

Validate uniformity, not just detection. A panel can technically detect every target and still be unreliable, if recovery for target 3 is 80% and recovery for target 17 is 12%. Validation should report per-target capture efficiency and on/off-target ratio, not a single pooled sensitivity number for the whole panel.

Where Multiplexed Capture Matters Most Right Now

Infectious disease and pathogen panels. Syndromic panels that need to distinguish between a dozen or more related pathogens from a single respiratory or bloodstream sample live or die on specificity. Cross-reactive probes here do not just reduce yield, they produce false positives against related but clinically distinct organisms.

Liquid biopsy and biomarker panels. Circulating tumor DNA and cell-free RNA panels are working with vanishingly small input amounts to begin with. Every point of nonspecific background or uneven capture efficiency directly erodes an already thin signal, which is why background control matters disproportionately more here than in high-input applications.

Custom NGS target enrichment. Labs increasingly want gene panels tailored to a specific study rather than an off-the-shelf exome kit. That only becomes practical, cost-wise and turnaround-wise, if adding or removing a target from the panel does not require a full bait resynthesis cycle.

rRNA depletion alongside target capture. Some workflows now combine ribosomal RNA depletion with simultaneous enrichment of a transcript subset, effectively multiplexing a "remove this" operation with a "keep this" operation in the same reaction. That only works cleanly if the underlying capture chemistry keeps background low regardless of how many catcher sequences are present.

How LASSO Approaches Multiplexed Capture

LASSO was built around a programmable catcher strand: a short, sequence-specific element that determines what gets captured, decoupled from the physical pulldown step. Because specificity and capture are separated, adding catcher strands for additional targets does not introduce the compounding nonspecific background that bead-surface chemistries tend to accumulate as panels grow. LASSO's near-zero background by design and up to 20-fold higher binding capacity than commercial microbeads both come from this separation, and both matter more as panel size increases rather than less.

The redesignability is the other half of the story. Because the target is defined by swapping the catcher strand rather than resynthesizing a bait library, extending or trimming a panel is a design change, not a manufacturing project. That applies across DNA, RNA, and protein targets from the same underlying platform, so a diagnostic panel that eventually needs to add a protein biomarker alongside its nucleic acid targets does not require switching chemistries entirely.

For labs building out multiplexed panels for diagnostics or NGS, the practical takeaway is this: treat panel design as an exercise in uniformity and background control from the start, not as single-target capture scaled up after the fact. The chemistry you choose either compounds those problems as the panel grows or it does not.